The Supreme Court has unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely watched by the generics industry.
June 4, 2026 11:04 AM EDT
PharmaLaw
Supreme Court sides with Hikma in 'skinny label' case
Nicole DeFeudis
The Supreme Court has unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was …
Supreme Court backs generic drugmaker in 'skinny labeling' case
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
Treatment for millions at stake in 'skinny label' Supreme Court case
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Generic drugmakers gain key victory in ‘skinny label’ patent case
US supreme court backs generic drugmaker over Irish-American firm in patent case
Supreme Court backs generic drugmaker in patent case
FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails
Ozempic maker takes on local firm
Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with…
With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma…
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research…
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching…
Dublin-based Amarin loses appeal over patent on its cardiovascular drug Vascepa
